RecallHawk

AMPICILLIN AND SULBACTAM

HQ SPECLT PHARMA

Summary

FDA approved AMPICILLIN AND SULBACTAM by HQ SPECLT PHARMA. ANDA (Generic) approval (Labeling) on 2026-01-19. INJECTABLE, INJECTION.

Details

Source

Drug Approval

External ID

ANDA065176-24

Action Date

2026-01-19

Status

Approved

Category

drug

Product Code

ANDA (Generic)

Product Description

AMPICILLIN AND SULBACTAM, INJECTABLE, INJECTION. Application: ANDA065176

Context & Analysis

HQ SPECLT PHARMA has 2 FDA actions in our database.

Frequently Asked Questions

How often does HQ SPECLT PHARMA have FDA actions?

HQ SPECLT PHARMA has 2 FDA actions in our database, including 0 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "ANDA065176-24" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions